• Gowhar Rashid, Gulzar A Bhat, Tahseen Bilal Rather, Kulsum Akhtar, Ishrat Parveiz, Syed Nisar Ahmad, Malik Tariq Rasool, Farooq Ahmad Jan, Mohanad Diab, Wael Hafez, and Syed Mudassar.
• Department of Clinical Biochemistry, SKIMS, Srinagar, India.
• Medicine (Baltimore). 2023 Nov 24; 102 (47): e36256e36256.

AbstractNumerous research studies have investigated the relationship between ABO and Rhesus (Rh) blood groups and the risk of various cancers, yielding diverse findings. While these blood groups have been established as prognostic factors in some cancers, their relevance to colorectal cancer (CRC) remains uncertain. This research aims to determine the link between CRC and the ABO and Rh blood groups and explore any potential implications for disease survival. A hospital-based prospective observational study was conducted from March 2019 to March 2022 at the Sher-I-Kashmir Institute of Medical Sciences in Srinagar, India. A total of 246 patients with confirmed colorectal cancer were enrolled in the study. Our study observed that blood type B (33.74%) and Rh-positive (91.87%) blood types were the most prevalent, surpassing other blood groups. No statistically significant associations were identified between the blood groups and the studied xenobiotic-metabolizing enzyme gene variants. The study observed a heightened risk of CRC in patients with advanced cancer stages and lymphovascular invasion (P-value < .05). On follow-up, there were no statistically significant differences in 3-year survival rates observed between ABO and Rh blood groups. This study's findings suggest that ABO and Rh blood groups are not associated with the risk of CRC or overall survival among CRC patients. Further clinical studies are needed to establish the precise relationship between blood groups and CRC risks, as well as their implications for the prognosis of CRC patients.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

6 keywords...

hide…